Karmanos Cancer Institute

McLaren Greater Lansing

Lansing, MI

Sorting 1 by

Not yet accepting

KER-050

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Learn more
  • Growth Factor
  • Phase 2
  • Has results